Brind.

Bio-Techne is facing scrutiny regarding its market performance and the growth of Protein Sciences, questioned by a UBS analyst.

1 report, 1 independent Updated Aug 13

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Bio-Techne Protein Sciences UBS

How it developed

Newest first. Tap a step to see who reported it.

Sep 6Bio-Techne sells products in Africa and the Middle East and operates through its Protein Sciences segment.Sub-event
Jun 8Protein Sciences accounts for 72% of net sales for Bio-Techne.Sub-event
Aug 13Bio-Techne seeks clarity on Protein Sciences growth amid questions from a UBS analyst.1 source
- StockStory

Keep exploring

The entities involved

Bio-Techne
company
- Bio-Techne has entered a strategic partnership with Spear Bio to distribute its immunoassays, advancing therapeutic development.Sun 13:32
- Trump pledged to unleash American oil and gas, involving MBX Biosciences, Inc.Sun 05:01
Protein Sciences
Pharmaceutical company in Connecticut, United States

Nothing else this week.
UBS
Swiss multinational investment bank and financial services company
- The Trump administration threatens tariffs on Switzerland, leading Switzerland to seek a new trade agreement with the US.Mon 00:13
- Following the acquisition of Credit Suisse, the Swiss parliament proposed new banking regulations for UBS.Sun 10:25

Coverage

Newest first; wire copies grouped

Aug 13StockStoryThe 5 Most Interesting Analyst Questions From Bio-Techne’s Q2 Earnings Call Bio-Techne’s second quarter results were met with a negative market reaction despite topping Wall Street’s revenue and prof